Chinese biotech startup D3 Bio, a precision medicine developer, has closed its Series A funding round at $200 million to support the development of the firm’s portfolio in oncology and immunology.
Chinese private equity firm Boyu Capital, Matrix Partners China, Sequoia Capital China, Singapore state investor Temasek and Hong Kong-listed pharma WuXi AppTec’ corporate venture fund joined the round.
